Abstract
Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords “treatment-resistant depression”, “major depressive disorder”, “adjunctive”, “refractory” and “augmentation”. From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports that adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted.
Keywords: Antidepressant, antipsychotic, diagnosis treatment, glutamate, monoamines, major depressive disorder.
Current Neuropharmacology
Title:Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Volume: 13 Issue: 5
Author(s): Rafael T. de Sousa, Marcus V. Zanetti, Andre R. Brunoni and Rodrigo Machado-Vieira
Affiliation:
Keywords: Antidepressant, antipsychotic, diagnosis treatment, glutamate, monoamines, major depressive disorder.
Abstract: Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords “treatment-resistant depression”, “major depressive disorder”, “adjunctive”, “refractory” and “augmentation”. From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports that adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted.
Export Options
About this article
Cite this article as:
de Sousa Rafael T., V. Zanetti Marcus, R. Brunoni Andre and Machado-Vieira Rodrigo, Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics, Current Neuropharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570159X13666150630173522
DOI https://dx.doi.org/10.2174/1570159X13666150630173522 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
Call for Papers in Thematic Issues
Advances in Neuroinflammation and Neuroprotection: Mechanisms and Therapeutic Frontiers
It offers a comprehensive exploration of neuroinflammatory and neuroprotective pathways that play central roles in a range of neurological disorders, including stroke, traumatic brain injury, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. This issue invites research on the cellular and molecular mechanisms driving neuroinflammation, such as the roles of ...read more
Advances in paediatric and adult brain cancers: emerging targets and treatments
Brain tumors are the most common solid tumors affecting children and adolescents, with up to 5,000 children diagnosed per year. Pediatric brain tumors, because of their location, are often untreatable and their clinical management can cause significant long-term impairment to intellectual and neurological function with epilepsy and neurodegeneration. Other than ...read more
Cannabinoids in Health and Disease.
The role of cannabinoids in human physiology and disease has become a dynamic and rapidly evolving field of research, offering new insights into the potential of these compounds. With advancements in neuropharmacology and clinical trials, cannabinoids are now at the forefront of innovative approaches to treat several conditions. This special ...read more
Cannabis in Health and Disease
Cannabis-based products span a history of over 4,000 years, with their regular purposes in numerous religious rituals, traditional systems of medicine, cosmetics, and hedonic activities. The discovery and cloning of cannabinoid receptors in mammalian tissues provided direct evidence of the physiological significance of targeting these receptors with endogenously synthesized and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Truly “Rational” Polytherapy: Maximizing Efficacy and Minimizing Drug Interactions, Drug Load, and Adverse Effects
Current Neuropharmacology Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Current Neuropharmacology FMRI of the Emotions: Towards an Improved Understanding of Amygdala Function
Current Medical Imaging Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews New Insights into Pre-, Intra- and Post-Operative Brain Mapping in Low- Grade Glioma Surgery: Towards a Longitudinal Study of Cerebral Plasticity
Current Medical Imaging Targeting BLyS in Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Exosomes: Natural Carriers for siRNA Delivery
Current Pharmaceutical Design Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets Comparison of Changes in Cognitive Functions of Post-stroke Patients with the Computer-based Cognitive Intervention (PABLO System) and Conventional Cognitive Intervention (Paper-pencil Method)
Current Psychiatry Research and Reviews Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Anticonvulsant Effect of the Essential Oil and Methanolic Extracts of <i>Zataria multiflora</i> Boiss
Central Nervous System Agents in Medicinal Chemistry Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology A Comprehensive Review on Therapeutic Potential of Chrysin in Brain Related Disorders
CNS & Neurological Disorders - Drug Targets Understanding Genotypes and Phenotypes of the Mutations in Voltage- Gated Sodium Channel α Subunits in Epilepsy
CNS & Neurological Disorders - Drug Targets PET Tracers for Imaging of ABC Transporters at the Blood-Brain Barrier: Principles and Strategies
Current Pharmaceutical Design Perspectives on Phytochemicals as Antibacterial Agents: An Outstanding Contribution to Modern Therapeutics
Mini-Reviews in Medicinal Chemistry Dynamic Changes in the Proteomic Profile of Mesial Temporal Lobe Epilepsy at Different Disease Stages in an Immature Rat Model
Protein & Peptide Letters